vertilmicin

structure in first source

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

1.	Infections 10/01/2009 - "In this study, we further evaluated the efficacy of vertilmicin in vivo in systemic and local infection animal models. " 10/01/2009 - "We demonstrated that vertilmicin had relatively high and broad-spectrum activities against mouse systemic infections caused by Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Enterococcus faecalis. " 10/01/2009 - "The therapeutic efficacy of vertilmicin was further confirmed in local infection models of rabbit skin burn infection and mouse ascending urinary tract infection."
2.	Urinary Tract Infections (Urinary Tract Infection) 10/01/2009 - "The therapeutic efficacy of vertilmicin was further confirmed in local infection models of rabbit skin burn infection and mouse ascending urinary tract infection."
3.	Burns 10/01/2009 - "The therapeutic efficacy of vertilmicin was further confirmed in local infection models of rabbit skin burn infection and mouse ascending urinary tract infection."
4.	Body Weight (Weight, Body) 12/15/2005 - "The pharmacokinetics of vertilmicin was studied in 24 rats following intramuscular injection (i.m.) of different doses (4, 8, 16, 32 mg/kg of body weight). "

1.	Intramuscular Injections